Inovio Accelerates Towards Milestone Approval with Strong Q2 Performance
Inovio, the pioneering biotechnology company, has reported a significant step forward in its second quarter of 2026 financial results. The company's President and CEO, Dr. Jacqueline Shea, led the conference call that revealed Inovio's unwavering commitment to revolutionizing the treatment of chronic diseases.
With the FDA's ongoing review of the BLA for INO-3107 nearing completion, Inovio remains on track for its October 30th target PDUFA date. Dr. Shea highlighted the regulatory progress achieved during Q2, including the completion of late-cycle reviews and pre-licensure inspections by the FDA. Additionally, the agency granted an informal clinical meeting where Inovio presented the substantial data supporting INO-3107's efficacy and safety in treating RRP.
INO-3107, a DNA medicine, is poised to become the new standard of care for patients suffering from this devastating disease. With its highly differentiated approach, INO-3107 has shown remarkable potential in reducing the need for surgery-related treatments. The company believes that there remains significant unmet need in this area and that their product can fill this gap effectively.
Inovio's commercial launch preparations are also gaining momentum. Steve Egge, Chief Commercial Officer, expanded on the company's efforts to build critical infrastructure, including a recent equity offering that provided $18.3 million in net proceeds to support these initiatives. This funding is expected to extend Inovio's runway into late first quarter 2027 and through a potential launch of INO-3107.
Meanwhile, Inovio's partnerships have enabled significant progress with other promising candidates across its pipeline. ApolloBio, the company's partner for VGX-3100 in Greater China, announced positive top-line results from its pivotal phase III trial as a treatment for HPV 16 or 18 positive cervical dysplasia.
Dr. Shea emphasized Inovio's dedication to advancing its DPROT technology platform and highlighted the company's capital resources, including an estimated operational net cash burn of approximately $18 million for the third quarter of 2026. With sufficient cash resources expected through a potential launch of INO-3107, Inovio remains confident in its ability to navigate the competitive landscape effectively.
The recent developments mark a significant milestone for Inovio as it continues to push the boundaries of DNA medicines. The company's commitment to innovation and its unwavering dedication to delivering life-changing treatments make it an exciting player in the biotech industry.
